Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

Next Previous
Trial Profile

An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zanubrutinib (Primary) ; Bendamustine; Rituximab; Venetoclax
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms SEQUOIA
  • Sponsors BeiGene

    • Most Recent Events

    • 31 Jan 2024 According to a BeiGene media release, based on the results from SEQUOIA and ALPINE trials, the Governments of Ontario and Quebec have publicly listed BRUKINSA (zanubrutinib), for the treatment of adults living with chronic lymphocytic leukemia (CLL), The Regie de l'assurance maladie du Quebec listing came into effect December 13, 2023, and the Ontario Drug Benefit Program (ODB) added BRUKINSA on January 12, 2024.
    • 12 Dec 2023 Results of a biomarker sub-group analysis assessing PFS in both treatment arms in patients sub grouped based on various biomarkers, including several known negative prognostic factors for CLL presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 15 Jun 2023 Results presented at the 28th Congress of the European Haematology Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top